摘要
带状疱疹神经痛(HZN)是一种难治性神经病理性疼痛。随着年龄的增加,其发病率也呈上升趋势,带状疱疹后神经痛(PHN)的患病率也逐渐增加。因其疼痛剧烈,常持续数月数年之久,对工作生活影响巨大。如何减轻患者的疼痛程度、预防后遗神经痛等是治疗的关键。然而常规的药物治疗常出现头晕、嗜睡等不良反应,总体有效率低,不利于疼痛的控制和减轻。A型肉毒毒素(BTX-A)是肉毒杆菌释放的一种外毒素,其注射技术简单,通过作用神经肌肉接头的突触、抑制神经炎症反应等机制,可有效缓解PHN的疼痛程度、降低后遗神经痛的发生率。该文就BTX-A在PHN诊治中的应用进展进行综述。
Herpes zoster neuralgia(HZN)is a refractory neuropathic pain.Its incidence increases with age,along with higher prevalence of postherpetic neuralgia(PHN).The pain is severe and often lasts for months or even years,significantly impacting patients’work and life.How to reduce the pain level and prevent postherpetic neuralgia is the key to its treatment.However,conventional drug treatment often has adverse effects such as dizziness and drowsiness with low overall efficacy,which is not conducive to controlling and mitigating the pain.Botulinum toxin type A(BTX-A)is an exotoxin released by clostridium botulinum,which is simple to inject,and can effectively alleviate the pain level of PHN through mechanisms such as acting on synapses of neuromuscular junctions and inhibiting neuroinflammatory responses,thereby reducing the incidence of posterior neuralgia.This paper reviews the progress of BTX-A application in the diagnosis and treatment of PHN.
作者
李富波
龚格格
张悦
欧册华
LI Fubo;GONG Gege;ZHANG Yue;OU Cehua(Department of Painology,Affiliated Hospital of Southwest Medical University,Luzhou 646000,China;Department of Physical Diagnosis,Affiliated Hospital of Southwest Medical University,Luzhou 646000,China)
出处
《医药导报》
北大核心
2025年第8期1297-1302,共6页
Herald of Medicine
基金
四川省医学青年创新科研课题计划(Q23099)
泸州市人民政府-西南医科大学科技战略合作项目(2023LZXNYDJ018)
合江县人民医院-西南医科大学科技战略合作项目(2023HJXNYD05)。
